May 7, 2026

@michaelokun

Parkinson’s precision medicine is no longer theoretical. PPMI is helping reshape the future of how we define and study Parkinson’s disease. Precision medicine means using biologic, genetic and clinical information to better understand why disease differs from one person to another and to match therapies more precisely. Marek and colleagues describe in an editorial in Annals of Neurology how the Parkinson’s Progression Markers Initiative (PPMI) has evolved over 15 years from a biomarker discovery effort into a global precision medicine platform for PD and related synucleinopathies. Key points: - PPMI has collected comprehensive clinical, imaging, biomarker and genetic data from thousands of participants worldwide and shared these data openly w/ the scientific community. - The initiative helped shift the field from defining Parkinson’s disease only by symptoms to defining disease biology using biomarkers such as alpha-synuclein seed amplification assays and dopamine imaging. - New remote tools such as myPPMI are expanding global participation and enabling large scale biologic and clinical data collection for future precision therapeutic trials. My take: This paper captures one of the most important transformations in Parkinson’s research. We are moving away from lumping all Parkinson’s disease together and toward understanding the biology driving each individual case. This transition matters because biology based classification may facilitate matching the right therapies to the right folks at the right time. PPMI has also shown the power of open science and collaboration across academia, foundations, industry and study participants. Here are 5 points that resonated w/ me: 1- PD likely begins many years before classic motor symptoms emerge. 2- Biomarkers are helping identify disease earlier and may eventually support prevention focused trials. 3- Precision medicine may reduce the one size fits all approach that has limited previous clinical trials. 4- Remote platforms such as myPPMI may democratize research participation and expand diversity across future studies. 5- Open data sharing has accelerated discovery worldwide. #michaelokun #fixelinstitute #parkinson